Phase Zero: "Open for Business"
This article was originally published in RPM Report
Executive Summary
Despite a setback presented by a small micro-dosing trial in the UK, FDA says its "Phase Zero" program has appropriate safeguards in place and should be pursued by biopharmaceutical companies.